Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PAN 811

Drug Profile

PAN 811

Alternative Names: PAN-811

Latest Information Update: 17 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Panacea Pharmaceuticals
  • Class Antidementias; Cytoprotectives; Neuroprotectants; Pyridines; Small molecules; Thiosemicarbazones
  • Mechanism of Action Antioxidants; Chelating agents; Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease; Stroke

Most Recent Events

  • 16 May 2018 Panacea Pharmaceuticals is now called Sensei Biotherapeutics
  • 07 Nov 2007 Pharmacodynamics data presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007) ,
  • 21 Jul 2006 Data presented at the 10th International conference on Alzeimer's Disease and Related Disorders (ICAD-2006) have been added to the Alzheimer's disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top